Rezolve AI stock price target raised to $15 from $10 at Maxim Group

Maxim Group raised its price target on Rezolve AI Ltd. (RZLV) to $15 from $10, maintaining a Buy rating, following the company's strong first-half 2025 results which exceeded revenue and adjusted EBITDA expectations. The AI firm significantly increased its annualized recurring revenue (ARR) guidance for 2025 to $150 million and introduced a 2026 target of $500 million, prompting Maxim to substantially raise its revenue forecasts for both years. This positive outlook, supported by impressive 81.87% gross profit margins and a 264% stock gain over six months, reflects robust investor interest despite some mixed earnings results and an InvestingPro suggestion of potential overvaluation.

Analysis

Rezolve AI (NASDAQ: RZLV) is demonstrating significant operational momentum, underscored by its first-half 2025 results which surpassed revenue and adjusted EBITDA expectations. The company's annualized recurring revenue (ARR) is accelerating rapidly, growing from $70 million in June 2025 to $90 million by September 2025, alongside a doubling of its customer base. This performance prompted management to increase its December 2025 ARR guidance by 50% to a minimum of $150 million and to introduce a 2026 ARR target of $500 million. This bullish outlook is supported by a strong gross profit margin of 81.87% and has triggered a series of analyst upgrades. Maxim Group raised its price target to $15.00, citing substantially higher revenue forecasts in its DCF model, while H.C. Wainwright and Cantor Fitzgerald also increased their targets to $10 and $7, respectively. However, investors should note potential headwinds: the stock has already gained 264% in six months, and an InvestingPro analysis suggests it may be overvalued. Furthermore, a reported revenue shortfall in the second quarter, with revenue of $4.88 million against a $6.75 million forecast, indicates potential execution risk despite the overall positive sentiment.

Key Decisions for Investors

• Given the accelerated ARR growth, significantly raised 2025 and 2026 guidance, and multiple analyst price target increases, investors with a high-risk tolerance could view the current momentum as a signal of further upside, predicated on the company's ability to execute its aggressive growth plan.
• Investors should exercise caution, noting the stock's 264% gain over six months, an external analysis suggesting potential overvaluation, and a recent quarterly revenue miss which signals that execution risk remains a key factor.
• Monitor upcoming quarterly reports closely for continued ARR and customer acquisition momentum to validate the revised guidance, as any shortfall could significantly impact the stock's premium valuation.